Rituximab in thrombotic primary antiphospholipid syndrome: a pilot study from a single centre in China
- 31 May 2021
- journal article
- letter
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 80 (6), 820-822
- https://doi.org/10.1136/annrheumdis-2020-219303
Abstract
No abstract availableKeywords
Funding Information
- Clinical Research Plan of SHDC (SHDC2020CR4011)
- National Natural Science Foundation of China (81801592)
- Shanghai Sailing Program (18YF1414100)
This publication has 10 references indexed in Scilit:
- Continous Rituximab treatment for recurrent diffuse alveolar hemorrhage in a patient with systemic lupus erythematosus and antiphosholipid syndromeRespiratory Medicine Case Reports, 2017
- Catastrophic antiphospholipid syndrome treated with rituximab: A case reportEuropean Journal of Rheumatology, 2017
- Inefficacy of plasma exchanges associated to rituximab in refractory obstetrical antiphospholipid syndromeLa Presse Médicale, 2015
- Rituximab: an emerging treatment for recurrent diffuse alveolar hemorrhage in systemic lupus erythematosusLupus, 2014
- 14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment TrendsAutoimmunity Reviews, 2014
- Current Concepts and New Trends in the Diagnosis and Management of Recurrent MiscarriageObstetrical & Gynecological Survey, 2013
- How we diagnose the antiphospholipid syndromeBlood, 2009
- B cell depletion therapy for patients with systemic lupus erythaematosus results in a significant drop in anticardiolipin antibody titresAnnals Of The Rheumatic Diseases, 2007
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshopArthritis & Rheumatism, 1999